Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Assets Average (2016 - 2025)

Historic Assets Average for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Q4 2025 value amounting to $1.5 billion.

  • Arrowhead Pharmaceuticals' Assets Average rose 3881.97% to $1.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.5 billion, marking a year-over-year increase of 3881.97%. This contributed to the annual value of $1.3 billion for FY2025, which is 3252.64% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Assets Average stood at $1.5 billion for Q4 2025, which was up 3881.97% from $1.4 billion recorded in Q3 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Assets Average peaked at $1.5 billion during Q4 2025, and registered a low of $628.0 million during Q1 2021.
  • Its 5-year average for Assets Average is $917.1 million, with a median of $791.2 million in 2022.
  • In the last 5 years, Arrowhead Pharmaceuticals' Assets Average crashed by 1209.97% in 2023 and then skyrocketed by 6359.76% in 2025.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Assets Average stood at $674.3 million in 2021, then increased by 17.41% to $791.7 million in 2022, then fell by 12.1% to $695.9 million in 2023, then surged by 54.72% to $1.1 billion in 2024, then surged by 38.82% to $1.5 billion in 2025.
  • Its Assets Average stands at $1.5 billion for Q4 2025, versus $1.4 billion for Q3 2025 and $1.5 billion for Q2 2025.